Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer
Cytotoxic chemotherapy remains an important treatment for patients with non-small cell lung cancer (NSCLC) either alone or in combination with immunotherapy. Studies demonstrating the efficacy of first line treatment with immune checkpoint inhibitors (ICI) alone and in combination with chemotherapy have led to new first-line treatment options for patients with NSCLC [1 –3]. Carboplatin, pembrolizumab and either paclitaxel or nab-paclitaxel are now standard first line options for patients with lung squamous cell carcinoma (LSCC) .
Abstract MicroRNAs (miRNAs) are short single-stranded RNAs, measuring 21 to 23 nucleotides in length and regulate gene expression at the post-transcriptional level through mRNA destabilization or repressing protein synthesis. Dysregulation of miRNAs can lead to tumorigenesis through changes in regulation of key cellular processes such as cell proliferation, cell survival, and apoptosis. miR-125a-5p has been implicated as a tumor suppressor miRNA in malignancies such as non-small cell lung cancer and colon cancer. However, the role of miR-125a-5p has not been fully investigated in head and neck squamous cell carcin...
This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.
ConclusionsThere are subsets of patients in which one or the other between UFT and CBDCA/PTX is significantly more effective. Selection of adjuvant therapy for NSCLC patients needs to be made taking into consideration the pStage and histological subtype.
The objective of this study was to investigate the diagnostic performance of serum THBS2 in early-stage non-small-cell lung cancer (NSCLC). Serum THBS2 and Cyfra21-1 level were evaluated in blood samples of 112 patients from NSCLC groups and 51 healthy control groups. Receiver operator characteristic (ROC) curves were used to evaluate the diagnostic significance. Serum THBS2 level was significantly up-regulated in NSCLC patients compared with healthy control subjects (p
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths worldwide . Non-small cell lung cancer (NSCLC) accounts for 85%-90% of lung cancer cases and includes two subtypes: lung squamous cell carcinoma and lung adenocarcinoma . The survival of patients with lung cancer is strongly related to the cancer stage as evidenced by a steep decrease in the 5-year overall survival rate from 82% in stage IA to 6% in stage IV . However, in routine clinical practise, many patients with early stage lung cancer are not diagnosed in due time because they are often asymptomatic .
aring;rd L Abstract Introduction: We hypothesized that gross tumor volume (GTV) of primary tumor (GTVT) and nodal volumes (GTVN) were predictors of first failure site in non-small cell lung cancer (NSCLC). We aimed at also comparing the prognostic model's complexity to its ability to generate absolute risk predictions with emphasis on variables available at the time of diagnosis. Materials and methods: Three hundred and forty-two patients treated with definitive chemoradiotherapy (CRT) for adenocarcinoma (AC) or squamous cell carcinoma (SCC) in 2009-2017 were analyzed. Clinical data, standardized uptake values on ...
Conclusion: IOV in target volume delineation increases during treatment, where a disparity in institutional adaptation practices adds to the conventional causes of IOV. Consensus guidelines are urgently needed. PMID: 31271079 [PubMed - as supplied by publisher]
CONCLUSIONS: Through transcriptome analysis, we identified candidate genes, paired microRNAs and pathways for differentiating LUAD and LUSC, and they can provide novel differential diagnosis and therapeutic strategies for LUAD and LUSC. PMID: 31270041 [PubMed - in process]
Conclusions: This study used gene expression data from a large cohort of patients to explore the molecular differences between lung ADC and SQCC.
Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum-based therapy. However, treatment alternatives for patients with nivolumab-refractory are limited, and a constant opinion is not provided.Recently, accumulating studies have demonstrated that chemotherapy after immune checkpoint inhibitor treatment may induce better objective responses in patients with advanced non-small cell lung cancer.